vs

Side-by-side financial comparison of Ready Capital Corp (RC) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Ready Capital Corp is the larger business by last-quarter revenue ($13.1M vs $12.5M, roughly 1.1× Avidity Biosciences, Inc.). Avidity Biosciences, Inc. runs the higher net margin — -1398.3% vs -1772.7%, a 374.4% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -73.8%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -48.0%).

Ready Capital Corp is a leading US-based commercial real estate finance firm. It offers tailored lending solutions including multifamily property loans, small balance commercial real estate mortgages, construction financing, and mortgage servicing services. Its core client segments include real estate investors, small business operators, and property developers across the United States.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

RC vs RNA — Head-to-Head

Bigger by revenue
RC
RC
1.1× larger
RC
$13.1M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+507.8% gap
RNA
434.0%
-73.8%
RC
Higher net margin
RNA
RNA
374.4% more per $
RNA
-1398.3%
-1772.7%
RC
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-48.0%
RC

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
RC
RC
RNA
RNA
Revenue
$13.1M
$12.5M
Net Profit
$-232.6M
$-174.4M
Gross Margin
Operating Margin
-2013.3%
-1513.5%
Net Margin
-1772.7%
-1398.3%
Revenue YoY
-73.8%
434.0%
Net Profit YoY
26.1%
-117.0%
EPS (diluted)
$-1.43
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RC
RC
RNA
RNA
Q4 25
$13.1M
Q3 25
$85.4M
$12.5M
Q2 25
$16.9M
$3.8M
Q1 25
$40.2M
$1.6M
Q4 24
$50.1M
$3.0M
Q3 24
$107.2M
$2.3M
Q2 24
$51.0M
$2.0M
Q1 24
$48.5M
$3.5M
Net Profit
RC
RC
RNA
RNA
Q4 25
$-232.6M
Q3 25
$-16.7M
$-174.4M
Q2 25
$-53.7M
$-157.3M
Q1 25
$82.0M
$-115.8M
Q4 24
$-314.8M
$-102.3M
Q3 24
$-7.3M
$-80.4M
Q2 24
$-34.2M
$-70.8M
Q1 24
$-74.2M
$-68.9M
Operating Margin
RC
RC
RNA
RNA
Q4 25
-2013.3%
Q3 25
-31.5%
-1513.5%
Q2 25
-524.9%
-4448.7%
Q1 25
-8360.9%
Q4 24
-629.0%
-4069.6%
Q3 24
-14.8%
-4200.9%
Q2 24
-157.0%
-4040.4%
Q1 24
-217.9%
-2178.6%
Net Margin
RC
RC
RNA
RNA
Q4 25
-1772.7%
Q3 25
-19.6%
-1398.3%
Q2 25
-317.7%
-4089.3%
Q1 25
203.7%
-7360.0%
Q4 24
-628.8%
-3439.5%
Q3 24
-6.8%
-3441.7%
Q2 24
-67.1%
-3461.8%
Q1 24
-152.8%
-1943.4%
EPS (diluted)
RC
RC
RNA
RNA
Q4 25
$-1.43
Q3 25
$-0.13
$-1.27
Q2 25
$-0.34
$-1.21
Q1 25
$0.46
$-0.90
Q4 24
$-1.89
$-0.80
Q3 24
$-0.07
$-0.65
Q2 24
$-0.23
$-0.65
Q1 24
$-0.44
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RC
RC
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$207.8M
$350.2M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$1.5B
$1.9B
Total Assets
$7.8B
$2.1B
Debt / EquityLower = less leverage
0.89×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RC
RC
RNA
RNA
Q4 25
$207.8M
Q3 25
$147.5M
$350.2M
Q2 25
$162.9M
$243.9M
Q1 25
$205.9M
$254.2M
Q4 24
$143.8M
$219.9M
Q3 24
$181.3M
$370.2M
Q2 24
$226.3M
$575.8M
Q1 24
$166.0M
$471.4M
Total Debt
RC
RC
RNA
RNA
Q4 25
$1.4B
Q3 25
$1.4B
Q2 25
$1.4B
Q1 25
$1.5B
Q4 24
$1.3B
Q3 24
$1.2B
Q2 24
$1.2B
Q1 24
$1.1B
Stockholders' Equity
RC
RC
RNA
RNA
Q4 25
$1.5B
Q3 25
$1.8B
$1.9B
Q2 25
$1.8B
$1.2B
Q1 25
$1.9B
$1.3B
Q4 24
$1.8B
$1.4B
Q3 24
$2.2B
$1.5B
Q2 24
$2.3B
$1.2B
Q1 24
$2.4B
$830.9M
Total Assets
RC
RC
RNA
RNA
Q4 25
$7.8B
Q3 25
$8.3B
$2.1B
Q2 25
$9.3B
$1.4B
Q1 25
$10.0B
$1.5B
Q4 24
$10.1B
$1.6B
Q3 24
$11.3B
$1.6B
Q2 24
$11.8B
$1.3B
Q1 24
$12.0B
$951.5M
Debt / Equity
RC
RC
RNA
RNA
Q4 25
0.89×
Q3 25
0.78×
Q2 25
0.76×
Q1 25
0.77×
Q4 24
0.73×
Q3 24
0.54×
Q2 24
0.52×
Q1 24
0.46×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RC
RC
RNA
RNA
Operating Cash FlowLast quarter
$432.1M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RC
RC
RNA
RNA
Q4 25
$432.1M
Q3 25
$434.7M
$-156.2M
Q2 25
$-100.3M
$-199.7M
Q1 25
$108.5M
$-124.8M
Q4 24
$274.8M
$-99.9M
Q3 24
$221.1M
$-65.6M
Q2 24
$1.1M
$-65.0M
Q1 24
$23.4M
$-70.4M
Free Cash Flow
RC
RC
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
RC
RC
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
RC
RC
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
RC
RC
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
1.32×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons